Subscribe
2019-11-21-1-
21 November 2019GenericsRory O'Neill

LSPN Europe: new challenges for drug patent owners in Russia

Russian drug patent owners are being forced to come up with novel solutions to combat generic manufacturers trying to clear the way for competitor medicines.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
LSPN Europe: understand our business models, say in-house lawyers
26 November 2019   The best lawyers acting for life sciences companies make sure they fully understand their clients’ business models, said in-house counsel at Life Sciences Patent Network 2019.
Biotechnology
LSPN Europe: AIs should be named inventors, argues Dabus professor
21 November 2019   The team leader behind the world’s first artificial intelligence-generated patent application has said AI inventors will force major changes to the patent system.
Big Pharma
LSPN Europe: English contract law still ‘fit for purpose’ despite Brexit
21 November 2019   English law remains fit for purpose in international contracts in spite of Brexit, heard attendees at Life Sciences Patent Network Europe today, November 21.


Editor's picks

Killing the golden goose of US drug innovation (Part II): Drug pricing myths
Americas
Killing the golden goose of US drug innovation (Part II): Drug pricing myths
12 September 2025

Editor's picks

Americas
Killing the golden goose of US drug innovation (Part II): Drug pricing myths
12 September 2025
Americas
Smart ringleader: Could Ōura’s market dominance be under threat?
5 September 2025
Americas
Why Masimo’s ‘rare’ move pushes Apple case into uncharted territory
3 September 2025
Europe
Sandoz blocked by UK court from seeking Xarelto profits
2 September 2025
Europe
UPC sees rising small molecule litigation with Pfizer in the hot seat
29 August 2025
Europe
Astellas win strengthens blockbuster drug's European position
20 August 2025

More features

The Quintara decision: Defining trade secrets in federal cases
To disclose or not: Pharma patents face new AI reality
Trade secrets go global: How brand owners face a high-stakes battlefront
Killing the golden goose of US drug innovation (Part II): Drug pricing myths
Former pharma GC brings in-house perspective to McGuireWoods
Sandoz eyes US biosimilar launch as Regeneron settles
Buchalter brings in new partner to head up medtech
Trump’s march-in rights threat: Why pharma is rethinking collaborations